Theriva Biologics Inc. is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company's lead candidate includes VCN-01, SYN-004 and SYN-020. Theriva Biologics Inc., formerly known as Synthetic Biologics Inc., is based in ROCKVILLE, Md.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-23.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -196.84% |
| Return on Assets (Trailing 12 Months) | -69.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.74 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.74 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.11 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.46 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 33.74M |
| Free Float | 33.51M |
| Market Capitalization | $8.68M |
| Average Volume (Last 20 Days) | 23.53M |
| Beta (Past 60 Months) | 0.47 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.67% |
| Percentage Held By Institutions (Latest 13F Reports) | 6.17% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |